Document is current

Any future updates will be listed below

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Crossref DOI link: https://doi.org/10.1038/srep07310

Published Online: 2014-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark